Telix Pharmaceuticals Limited (TLX) Stock Score, Valuation & Financial Research
Telix Pharmaceuticals Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 34/100.
Quick answer for TLX
Telix Pharmaceuticals Limited currently has a Wall Street Score of 34/100. The stored market price is $11.29. Its financial score is 54/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Telix Pharmaceuticals Limited does
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based
TLX financial snapshot
- Wall Street Score:
- 34/100
- Current price:
- $11.29
- Market capitalization:
- $3.82B
- Revenue:
- $1.39B
- Net income:
- $27.3M
- Free cash flow:
- $-57.7M
- Cash:
- $148.2M
- Total debt:
- $488.1M
- EPS:
- -0.02
- Financial score:
- 54/100
- Valuation score:
- 0/100
- Revenue score:
- 46/100
What stands out
- Reported year-over-year revenue growth is +0.7%.
- Free cash flow is $-57.7M, showing cash burn in the current stored period.
- The balance sheet shows $148.2M of cash versus $488.1M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 54/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TLX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.